Update shared on05 Sep 2025
With both the discount rate and future P/E for Mastek remaining essentially unchanged, the consensus analyst price target was maintained at ₹3093.
What's in the News
- Upcoming board meeting to review June 2025 quarterly financial results and consider re-appointment of Suresh Vaswani as Independent Director for a second term.
- CFO Raghavendra Jha has resigned due to personal reasons.
- Launched ADOPT.AI suite to accelerate enterprise AI adoption, including 80+ AI Agent assets, an AI Engineering Center of Excellence, and strategic partnerships with NVIDIA and Open Ana.
- Over 3,600 employees certified in foundational and advanced AI competencies through the Mastek AI Academy.
- Secured a contract with NHS England, in partnership with Templar Executives, to deliver senior cybersecurity training for NHS Boards and SIROs.
Valuation Changes
Summary of Valuation Changes for Mastek
- The Consensus Analyst Price Target remained effectively unchanged, at ₹3093.
- The Discount Rate for Mastek remained effectively unchanged, at 16.17%.
- The Future P/E for Mastek remained effectively unchanged, moving only marginally from 26.59x to 26.60x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.